IL4 and Increased total eosinophil count: Pascolizumab (a humanized monoclonal antibody anti-IL-4) inhibits the interaction between IL-4 and its receptor, provoking the repression of Th2 cell differentiation, eosinophilia, and IgE up-regulation of all processes of the early phase of asthma.